Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Res 178 , 1324 (2016)
GLP-1 receptor agonists have transformed weight management for millions, with clinical trials showing average losses of 15-22% body weight
(semaglutide)(cagrilintide)(NovoPen 4 penfill) 7 AM833 ( (cagrilintide)) (semaglutide) 1 These non-clinical data may indicate that when a dual-chamber device is used to administer semaglutide and cagrilintide in a single injection, an enhanced effect is obtained
US$ 26.50
US$ 26.86
US$ 28.02
US$ 25.47
US$ 21.54
US$ 24.68
US$ 21.64
